Skip to main content
logo
Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
16.93
-0.03 (-0.18%)
Oct 2, 2026, 4:00 PM EDT - Market closed

Janux Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
241010.598.088.613.64
Revenue Growth
5366.97%-5.55%30.99%-6.14%136.79%-
Gross Profit
-99.98-115.9-57.8-46.84-44.83-22.6
Operating Income
-143.56-157.67-98.85-72.98-67.09-32.93
Net Income
-102.59-113.63-68.99-58.29-63.06-32.67
Earnings Per Share
-1.64-1.83-1.28-1.32-1.52-1.39
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
970.91966.571,025344.03327.02374.97
Total Debt
20.9922.1423.0324.5425.310.19
Net Cash (Debt)
949.92944.431,002319.49301.71374.77
Net Cash Growth
-2.45%-5.76%213.68%5.89%-19.50%4696.76%
Net Cash Per Share
15.2115.2418.647.267.2815.93

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-41.25-82.24-43.81-50.58-42.92-16.98
Capital Expenditures
-0.67-1.04-0.36-1.85-6.45-1.48
Free Cash Flow
-41.93-83.28-44.17-52.43-49.37-18.46
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-598.15%-1576.67%-933.58%-902.87%-779.04%-905.39%
Pretax Margin
-427.47%-1136.25%-651.62%-721.18%-732.22%-898.32%
Profit Margin
-427.47%-1136.25%-651.62%-721.18%-732.22%-898.32%
FCF Margin
-174.69%-832.78%-417.20%-648.58%-573.24%-507.51%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
43.1383.00291.5461.2763.54225.73